Your browser doesn't support javascript.
loading
Modelling Tools to Characterize Acetaminophen Pharmacokinetics in the Pregnant Population.
Brookhuis, Sofie A M; Allegaert, Karel; Hanff, Lidwien M; Lub-de Hooge, Marjolijn N; Dallmann, André; Mian, Paola.
Afiliación
  • Brookhuis SAM; Princess Maxima Centre for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Allegaert K; Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium.
  • Hanff LM; Department of Clinical Pharmacology and Pharmacotherapy, KU Leuven, 3000 Leuven, Belgium.
  • Lub-de Hooge MN; Erasmus Medical Center (MC), Department of Hospital Pharmacy, 3015 GD Rotterdam, The Netherlands.
  • Dallmann A; Princess Maxima Centre for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Mian P; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Pharmaceutics ; 13(8)2021 Aug 20.
Article en En | MEDLINE | ID: mdl-34452263
This review describes acetaminophen pharmacokinetics (PK) throughout pregnancy, as analyzed by three methods (non-compartmental analyses (NCA), population PK, and physiologically based PK (PBPK) modelling). Eighteen studies using NCA were reported in the scientific literature. These studies reported an increase in the volume of distribution (3.5-60.7%) and an increase in the clearance (36.8-84.4%) of acetaminophen in pregnant women compared to non-pregnant women. Only two studies using population PK modelling as a technique were available in the literature. The largest difference in acetaminophen clearance (203%) was observed in women at delivery compared to non-pregnant women. One study using the PBPK technique was found in the literature. This study focused on the formation of metabolites, and the toxic metabolite N-acetyl-p-benzoquinone imine was the highest in the first trimester, followed by the second and third trimester, compared with non-pregnant women. In conclusion, this review gave an overview on acetaminophen PK changes in pregnancy. Also, knowledge gaps, such as fetal and placenta PK parameters, have been identified, which should be explored further before dosing adjustments can be suggested on an evidence-based basis.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Suiza